Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T13:26:36.652Z.
Calculation as of: 2026-10-06T13:26:36.652Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9cd3ead22764b77a02cf3e742533c366d0c9255af04c84535b20f2b2666bee2a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$70.03M
EV/EBITDA Ratio
N/A
TTM Avg
250.18x
3Y Avg
250.18x
5Y Avg
250.18x
Market Cap
$70.01M
EV/EBITDA Ratio
N/A
TTM Avg
161.81x
3Y Avg
161.81x
5Y Avg
161.81x
Market Cap
$69.05M
EV/EBITDA Ratio
260.01x
TTM Avg
103.53x
3Y Avg
75.29x
5Y Avg
64.49x
Market Cap
$67.11M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gain Therapeutics, Inc. (GANX) | $72.09M | N/A | N/A | N/A | N/A |
| iBio, Inc. (IBIO)vs › | $72.02M | N/A | N/A | N/A | N/A |
| Heron Therapeutics, Inc. (HRTX)vs › | $70.03M | N/A | 250.18x | 250.18x | 250.18x |
| MindWalk Holdings Corp. (HYFT)vs › | $70.01M | N/A | 161.81x | 161.81x | 161.81x |
| Hyperfine, Inc. (HYPR)vs › | $74.35M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIO)vs › | $69.43M | N/A | N/A | N/A | N/A |
| Champions Oncology, Inc. (CSBR)vs › | $69.05M | 260.01x | 103.53x | 75.29x | 64.49x |
| PDS Biotechnology Corporation (PDSB)vs › | $67.11M | N/A | N/A | N/A | N/A |
| Alps Group Inc (ALPS)vs › | $64.90M | N/A | N/A | N/A | N/A |
| Gossamer Bio, Inc. (GOSS)vs › | $65.08M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
